Company

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China's RMB 7.8 Billion Heart Failure Market
Generic drugsHKG: 0719

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China’s RMB 7.8 Billion Heart Failure Market

Shandong Xinhua Pharmaceutical Company Limited (HKG: 0719, SHE: 000756) announced that it has received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for Sacubitril/Valsartan Sodium Tablets (sacubitril…

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationDoer Biologics

Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment

Clinical trial approval / initiationHengrui Pharmaceuticals

Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Breakthrough therapyHengrui Pharmaceuticals

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

AstraZenecaCancer

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Show More